Answers are grounded in this paper and cite their sources.
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental state, occurring in approximately 4% of adults. Screening is recommended in at-risk groups. Diagnosis relies on an in-depth clinical interview (≥ 90 min), assessing symptoms over the past 6 months (and earlier), onset before age 12, presence across at least two life domains, and clinically significant impairment. Neuropsychological tests, neuroimaging, or electroencephalography (EEG) are not routine but may assist when comorbidities are suspected. Information from relatives is valuable, yet lack of a parent report does not preclude diagnosis. Medication response is not a diagnostic criterion. Clinicians should consider compensatory strategies and sex-specific presentations, particularly in women. Therapeutic management is multi-directional. Psychoeducation is essential. Psychosocial interventions (CBT/DBT, coaching) improve functioning and can be used alone or in combination with pharmacotherapy, which is also the first-line treatment for adults with moderate to severe impairment. Preferred agents are long-acting stimulants (extended-release methylphenidate, lisdexamfetamine) while atomoxetine is an alternative in cases of contraindications or risk of prescription drug abuse. During treatment, blood pressure (BP), heart rate (HR), body weight, and sleep should be monitored. A cardiovascular history should be taken before treatment, and an electrocardiography (ECG) is recommended before starting treatment in individuals with cardiovascular risk factors. The most common side effects are increased BP and HR, insomnia, decreased appetite, and weight loss. Comorbidity is common, and generally the most severe disorder should be treated first. Treatment of ADHD reduces the risk of suicidal behavior, substance abuse, and traffic accidents. Key words: ADHD, guidelines, assessment, management, pharmacotherapy, comorbidity. Autor do korespondencji/Corresponding author: dr n. med. Tomasz M. Gondek, ul. Zakładowa 9G/4, 50-231 Wrocław, e-mail: tomasz.m.gondek@gmail.com e82 Personalized Psychiatry 2025; 4 Tomasz M. Gondek, Filip Stramecki, Marta Cieśla, Karolina Ziegart-Sadowska, Kajetana Foryciarz, Patryk Główczyński, Anna Julia Krupa, Krzysztof Krysta, Anna Karolina Malec, Anna Rewekant, Anna Szczegielniak, Anna Szczubiał-Kamińska, Anna Taracha-Mocarska, Agata Tokarek, Anita Wojtkiewicz, Agata Todzia-Kornaś Wstęp: aktualizacja rekomendacji w zakresie diagnostyki i postępowania terapeutycznego u dorosłych z ADHD Niniejsze rekomendacje są wynikiem współpracy specjalistów z Sekcji Kształcenia Specjalizacyjnego Polskiego Towarzystwa Psychiatrycznego oraz innych organizacji działających na rzecz osób z zespołem nadpobudliwości psychoruchowej z deficytem uwagi (attention deficit hyperactivity disorder – ADHD), a ich celem jest rozpowszechnianie wiedzy i poprawa jakości opieki zdrowotnej w Polsce. Od czasu publikacji w 2024 r. naszego pierwszego wspólnego stanowiska dotyczącego ADHD u dorosłych [1] dostępne stały się w Polsce substancje lecznicze, które uprzednio wymagały procedury importu docel
No takes yet. Share an insight, caveat, or question.
Gondek et al. (2025) studied this question.
Synapse has enriched 7 related papers. Consider them for comparative context: